Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study - Wikidata - awgldk - TriplyDB

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q30384730

about

Major clinical research advances in gynecologic cancer in 2015 Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.Improved survival with bevacizumab in advanced cervical cancer Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.Primary debulking surgery for metastatic cervical adenocarcinoma: A case report.Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).Chemotherapy and molecular targeting therapy for recurrent cervical cancer Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.Ino80 promotes cervical cancer tumorigenesis by activating Nanog expression.Pharmacotherapy of cervical cancer.Chemoradiation in the management of cervix cancer: current status and future directions.Live-attenuated Listeria-based immunotherapy.Advances in cervical cancer pharmacotherapies.Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.Changing paradigms in the systemic treatment of advanced cervical cancer.Bevacizumab for the treatment of cervical cancer.Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix.Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.Analysis of 30 patients with persistent or recurrent squamous cell carcinoma of the cervix within one year after concurrent chemoradiotherapy Human papillomavirus in solid organ transplantation.Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases.Systemic therapy for cervical carcinoma - current status.Systematic prediction of target genes and pathways in cervical cancer from microRNA expression data.

P2860

Q28077183-719741C2-75D2-4BD6-AC30-F3131BB221C3 Q28086919-316327C6-2166-4B37-AB36-FA80941A7754 Q30354788-30523543-87C4-42A7-8724-DD0B7D98DF06 Q33566222-8590ABE2-6D9B-4412-A861-74429C9427CE Q33875938-53554E83-870E-4063-B947-3ED8D199B0FA Q33955742-F6A37D46-C401-42B4-A860-F919D73C4F2C Q34091240-3579F261-2595-42C3-A0C3-83DD0172E71C Q34159386-92B1C987-710C-49A3-8CF7-0F79C642FFF5 Q35776186-3A2C2F29-579B-4F59-A020-BF8A2EF13214 Q35876936-9CA85882-A77E-4FFB-8A16-60EC2375A1F0 Q36397805-9EEE1A16-B874-43D3-89B5-3CC11914E74D Q36701305-3F46F558-9523-44B7-ABA0-240DC418F441 Q36897266-D7C2527B-54AC-4ED4-9EE2-7FCE1DA3D44C Q36937771-39F1CE77-E80E-425B-AE87-06D0BCFF9E9C Q37036792-4108C0BE-EA0A-47F1-B735-1C0DD05FF62A Q37687811-7C766957-054E-4109-8990-7F182DDF23F7 Q37773995-9A4F0DFD-4D53-4F30-BEE9-57F9EF41059A Q38079973-2F5AC45E-9557-4EC4-BAFD-273A00A36D30 Q38105337-3A3455B6-35FD-4D9B-A3B1-E0610169AB06 Q38184593-ACCC610E-432B-4555-9B61-E33E5D2ECCF7 Q38341324-D40AC74C-1B0D-4272-9B1A-994C6331E7CE Q38373926-D997605A-2CE4-46E3-A84F-BD1F83C8FFA8 Q38554663-9485DC53-9EAB-40E4-9EF9-BCA33774F862 Q38706483-7CB3A5E0-3E4A-4B3A-97A6-9B24ABAAD3BC Q38769655-D9658245-AE20-4A80-ABD5-86B67F87EEB3 Q38828572-5B74B834-79AA-46F2-AB2C-43B02C488BFF Q41785844-8CD70BE4-0A5C-478B-8FBA-88358C5416F6 Q42272312-D69BC4C0-FCA8-4647-8139-9A2E8AD01B85 Q46457082-9719E07A-4C35-440A-97AE-FB48673C7374 Q48149693-7E1AB660-66EA-4569-96E0-DC1E53E8E89E Q48276220-C620BD53-7345-47B4-BBB7-633C2362C60C Q52570998-3D476750-9219-49B3-BB25-12D82CBE4726 Q55092108-B65C5FA2-3918-4786-B3C1-61C60994DBE2 Q55240591-CEFE5188-3481-44F8-92C8-F369776BF656

P2860

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q30384730

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prognostic factors for respons ...... necologic Oncology Group Study

@ast

Prognostic factors for respons ...... necologic Oncology Group Study

@en

type

label

Prognostic factors for respons ...... necologic Oncology Group Study

@ast

Prognostic factors for respons ...... necologic Oncology Group Study

@en

prefLabel

Prognostic factors for respons ...... necologic Oncology Group Study

@ast

Prognostic factors for respons ...... necologic Oncology Group Study

@en

P1433

Q30384730-67234B75-C25D-4100-8A2D-D4AF606FC256

P1476

Q30384730-194C94B6-15CB-453B-86F9-30107E7C3580

P2093

Q30384730-0C0F71CC-04EB-40E3-A299-C45B2DCC4A6E

Q30384730-28C16D8D-D42A-499E-AD17-9B6CE6428479

Q30384730-433D47BA-0540-4966-B8C8-287983077645

Q30384730-73E11766-09AE-4808-AF54-E03ECA33137D

Q30384730-D5F9DA74-2E3E-4C5D-BC69-9C35157F0EFF

Q30384730-DCAB7AFE-2363-4521-B0E1-880A5880C984

P2860

Q30384730-06A2D0F2-72D9-4047-B259-C77756BAD62B

Q30384730-3A832B55-0F8B-4F8F-8DD1-5AD8702567BD

Q30384730-3AB2CE6F-E636-47BB-9BE3-C31F8A38E2B7

Q30384730-4BC02D3A-B8D0-492C-AFD5-712646E58361

Q30384730-563F1063-44EC-4323-8ED7-DCB8523ED07A

Q30384730-59184475-B56F-4EEB-B7C8-29EF328CC924

Q30384730-61905BE0-822E-48B2-A4C2-BB9D9A618737

Q30384730-6568D576-708C-47F3-848E-26DBFFC743B1

Q30384730-750D224B-BE8C-4B7F-91C6-C2DC210A000D

Q30384730-7DDDB272-E7DA-40E8-B56E-06A357FCE7E0

P304

Q30384730-F6F36F9B-594A-41CE-BDDA-434708F7D31F

P31

Q30384730-7256B72A-B0A0-4FD6-93CE-7C69471DBD60

P356

Q30384730-D5F0885F-E2A9-4DCB-847A-5C15C5116B1F

P407

Q30384730-E3A80F40-9436-4A05-9039-8202B43D78B4

P433

Q30384730-794E321C-2EB9-423A-96C4-D3C45EB9B4A7

P478

Q30384730-C819202E-9E3D-455E-9340-2C9D64DF5E06

P577

Q30384730-ABE423B3-E9A3-448E-A4AC-9CBCA7178862

P698

Q30384730-5AD2C0B9-DF3D-4CE2-9F7F-97F7DFB52CD7

P921

Q30384730-930F8227-086F-4716-B1CD-93EB2386C46F

P932

Q30384730-49ED4D94-F46C-4D85-82DF-E320AC7EB0D7

P356

J.YGYNO.2009.09.006

P1433

Gynecologic Oncology

P1476

Prognostic factors for respons ...... necologic Oncology Group Study

@en

P2093

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Chunqiao Tian

http://www.w3.org/2001/XMLSchema#string

David H Moore

http://www.w3.org/2001/XMLSchema#string

George A Omura

http://www.w3.org/2001/XMLSchema#string

Harry J Long

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Bloss

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.

Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Neoadjuvant chemotherapy for cervical cancer.

Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.

Current status of chemotherapy for cancer of the cervix.

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt

Chemotherapy for advanced, recurrent, and metastatic cervical cancer.

Platinum resistance: the role of DNA repair pathways.

Racial disparities among patients with lung cancer who were recommended operative therapy.

P304

44-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2009.09.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19853287

http://www.w3.org/2001/XMLSchema#string

P921

P932

4470610

http://www.w3.org/2001/XMLSchema#string